insulin glulisine vs Insulin Lispro

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

insulin glulisine · Apidra

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT00290927 · Phase 3 · completed

The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.

Reported efficacy

Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly. (met)

Result source: NCT00135057

Insulin Lispro · Humalog

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01474538 · Phase 3 · completed

The study randomized 122 participants to receive both insulin lispro and insulin aspart in crossover order, with participants, investigators, and outcome assessors masked. Its primary clinical endpoint, HbA1c after 16 weeks, met the prespecified non-inferiority criterion for lispro versus aspart, with the upper confidence limit below the 0.4% margin.

Next expected readout: December 2026 · NCT06251635 (registry estimate)

Reported efficacy

Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Insulin Lispro 7.5 percentage of glycosylated hemoglobin (Standard Error 0.12) | Insulin Aspart 7.4 percentage of glycosylated hemoglobin (Standard Error 0.12) (met)

Result source: NCT01474538

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin glulisineInsulin Lispro
HbA1c, change-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
-1.2% vs -1.1%vs Insulin Glargine1.5 mg · wk 26 · n 138NCT01621178
20 other results
  • -1.6% vs -1.4% 1.5 mg · wk 26 · n 273 · Phase 3 · primary NCT01191268
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.6% vs -1.4% 0.75 mg · wk 26 · n 275 · Phase 3 · primary NCT01191268
  • -1.2% vs -1.3% wk 24 · n 148 · Phase 3 · primary NCT00666718
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 345 · Phase 3 · primary NCT02229227
  • -1.7% vs -1.4% wk 26 · n 684 · Phase 3 · primary NCT01468987
  • -1.5% vs -1.2% 1.5 mg · wk 52 · n 273 · Phase 3 · secondary NCT01191268
  • -1.4% vs -1.2% 0.75 mg · wk 52 · n 275 · Phase 3 · secondary NCT01191268
  • -1.1% vs -1.3% wk 24 · n 179 · Phase 3 · secondary NCT00666718
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.0% vs -1.1% wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9% vs -1.0% wk 12 · n 179 · Phase 3 · secondary NCT00666718
  • -0.9% vs -1.0% wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.7% vs -0.6% wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6% vs -0.5% wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1% vs -0.8% wk 16 · n 131 · Phase 4 · secondary NCT00393705
Body weight, change (kg)0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result
-2.8 vs 1.1vs Insulin Glargine1.5 mg · wk 26 · n 140NCT01621178
15 other results
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • 1.0 vs 1.2 wk 24 · n 187 · Phase 3 · secondary NCT00666718
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • -1.9 vs 2.4 wk 26 · n 349 · Phase 3 · secondary NCT02229227
  • -1.9 vs 2.4 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • 1.3 vs 2.2 wk 26 · n 682 · Phase 3 · secondary NCT01468987
  • -2.0 vs 2.1 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.7 vs 1.5 wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9 vs 0.8 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6 vs 0.7 wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • 0.3 vs 0.9 wk 16 · n 116 · Phase 3 · secondary NCT01474538
  • 1.3 vs 0.4 wk 16 · n 126 · Phase 4 · secondary NCT00393705
  • 2.6 vs 2.7 wk 48 · n 138 · Phase 4 · secondary NCT00664534
HbA1c below 7%22.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
32.9% vs 29.1%vs Insulin Glargine1.5 mg · wk 52 · n 152NCT01621178
3 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
Fasting plasma glucose, change—Not posted · NCT00135057-2.0 vs -1.5vs Insulin Lispro + Insulin Glarginewk 26 · n 345NCT02229227
4 other results
  • -2.0 vs -1.5 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.8 vs -1.2 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1 vs -0.9 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -1.3 vs -0.8 wk 4 · n 402 · Phase 3 · secondary NCT02229227
3-point MACE (% with event)—Not posted · NCT00135057—Not posted · NCT00551356

HbA1c, change

insulin glulisine
-0.5% vs -0.5%vs Insulin Lispron 115NCT01194258
2 other results
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
Insulin Lispro
-1.2% vs -1.1%vs Insulin Glargine1.5 mg · wk 26 · n 138NCT01621178
20 other results
  • -1.6% vs -1.4% 1.5 mg · wk 26 · n 273 · Phase 3 · primary NCT01191268
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.6% vs -1.4% 0.75 mg · wk 26 · n 275 · Phase 3 · primary NCT01191268
  • -1.2% vs -1.3% wk 24 · n 148 · Phase 3 · primary NCT00666718
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 345 · Phase 3 · primary NCT02229227
  • -1.7% vs -1.4% wk 26 · n 684 · Phase 3 · primary NCT01468987
  • -1.5% vs -1.2% 1.5 mg · wk 52 · n 273 · Phase 3 · secondary NCT01191268
  • -1.4% vs -1.2% 0.75 mg · wk 52 · n 275 · Phase 3 · secondary NCT01191268
  • -1.1% vs -1.3% wk 24 · n 179 · Phase 3 · secondary NCT00666718
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.0% vs -1.1% wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9% vs -1.0% wk 12 · n 179 · Phase 3 · secondary NCT00666718
  • -0.9% vs -1.0% wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.7% vs -0.6% wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6% vs -0.5% wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1% vs -0.8% wk 16 · n 131 · Phase 4 · secondary NCT00393705

Body weight, change (kg)

insulin glulisine
0.5 vs 0.2vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 48NCT00360698
1 other result
Insulin Lispro
-2.8 vs 1.1vs Insulin Glargine1.5 mg · wk 26 · n 140NCT01621178
15 other results
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • 1.0 vs 1.2 wk 24 · n 187 · Phase 3 · secondary NCT00666718
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • -1.9 vs 2.4 wk 26 · n 349 · Phase 3 · secondary NCT02229227
  • -1.9 vs 2.4 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • 1.3 vs 2.2 wk 26 · n 682 · Phase 3 · secondary NCT01468987
  • -2.0 vs 2.1 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.7 vs 1.5 wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9 vs 0.8 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6 vs 0.7 wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • 0.3 vs 0.9 wk 16 · n 116 · Phase 3 · secondary NCT01474538
  • 1.3 vs 0.4 wk 16 · n 126 · Phase 4 · secondary NCT00393705
  • 2.6 vs 2.7 wk 48 · n 138 · Phase 4 · secondary NCT00664534

HbA1c below 7%

insulin glulisine
22.4% vs 8.8%vs Insulin Glargine+Metformin+Glimepiridewk 24 · n 49NCT00360698
1 other result
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
Insulin Lispro
32.9% vs 29.1%vs Insulin Glargine1.5 mg · wk 52 · n 152NCT01621178
3 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178

Fasting plasma glucose, change

insulin glulisine
—Not posted · NCT00135057
Insulin Lispro
-2.0 vs -1.5vs Insulin Lispro + Insulin Glarginewk 26 · n 345NCT02229227
4 other results
  • -2.0 vs -1.5 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.8 vs -1.2 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1 vs -0.9 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -1.3 vs -0.8 wk 4 · n 402 · Phase 3 · secondary NCT02229227

3-point MACE (% with event)

insulin glulisine
—Not posted · NCT00135057
Insulin Lispro
—Not posted · NCT00551356
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. insulin glulisine: 6 of 6 rows · Insulin Lispro: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin glulisine
Rows use multiple source trials
Insulin Lispro
Rows use multiple source trials
HbA1c
absolute value · percentage points
7.5% (n=49) vs 7.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wka,b,c
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
7.4% (n=108) vs 7.55% (n=98) Glargine @ 48wkd,a,b,c
NCT00664534 · Phase 4 · registry result, not featured evidence
show 1 more dose
7.33% (n=158) vs 7.4% (n=163) Glargine @ 48wk
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7%
responder rate · % of participants
HbA1c < 7.0%
43.3% (n=187) vs 38.6% (n=189) Novolog Mix 70/30 @ 60wkd,e,a,b,f
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
44.1% (n=195) vs 38.1% (n=197) Novolog Mix 70/30 @ 60wk
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
36% (n=179) vs 50% (n=180) Glargine @ 24wke,a,b,f
HbA1c < 7.0%
NCT00666718 · Phase 3 · registry result, not featured evidence
Dropout rate
23.5%Lantus/Apidra-1g
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
20%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—h
NCT01474538 · Phase 3
show 18 more results
19.3%
NCT00664534 · Phase 4 · registry result, not featured evidence
15.2%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
4.7%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
12.7%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
—1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
—0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
10.3%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
19.7%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
18.8%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
—Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
9.6%ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
—Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
—Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
—
NCT02197520 · Phase 1 · registry result, not featured evidence
11.1%
NCT05893797 · Phase na · registry result, not featured evidence
Discontinued due to AEs
2.6%Lantus/Apidra-1g
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
2.6%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
—Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—h
NCT01474538 · Phase 3
show 18 more results
1.8%
NCT00664534 · Phase 4 · registry result, not featured evidence
0%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
0.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
3.5%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
—1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
—0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
1.7%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
7.1%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
4.4%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
—Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
0.5%ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
—Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
—Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
—
NCT02197520 · Phase 1 · registry result, not featured evidence
2.8%
NCT05893797 · Phase na · registry result, not featured evidence
Serious AEs
11.9%Lantus/Apidra-1g
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
11.3%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
2%
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
6.5%Aspart-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
0%Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
12.7%h
NCT01474538 · Phase 3
show 18 more results
4.1%
NCT00664534 · Phase 4 · registry result, not featured evidence
2.2%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
6.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
5.8%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
21.4%1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
25.3%0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
11.4%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
9.2%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
15.7%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
4.8%Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
7.5%Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
0%Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
0%Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
4.5%Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
0%Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
0%
NCT02197520 · Phase 1 · registry result, not featured evidence
8.3%
NCT05893797 · Phase na · registry result, not featured evidence
Most frequent reported AEs
g
any infections and infestations 42.3%
any musculoskeletal and connective tissue disorders 22.7%
any gastrointestinal disorders 16.5%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
any infections and infestations 34%
any musculoskeletal and connective tissue disorders 23.2%
any nervous system disorders 20.1%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
uterine leiomyoma 6.7%
arthralgia 6.5%
headache 6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 11.9%
diarrhoea 8.5%
nasopharyngitis 5.1%
NCT01194258 · Phase 2 · registry result, not featured evidence
h
nasopharyngitis 4.2%
nausea 4.2%
fatigue 3.4%
NCT01474538 · Phase 3
show 17 more results
pyrexia 3.6%
neuropathy peripheral 3%
diarrhoea 2.4%
NCT00664534 · Phase 4 · registry result, not featured evidence
nasopharyngitis 4.3%
bronchitis 2.2%
arthralgia 1.4%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nausea 9.3%
diarrhoea 7.8%
viral upper respiratory tract infection 6.3%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
blood creatinine increased 38.5%
nausea 19.8%
diarrhoea 16.1%
NCT01621178 · Phase 3 · registry result, not featured evidence
0.75 mg
blood creatinine increased 37.4%
diarrhoea 15.8%
nausea 14.2%
NCT01621178 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.1%
upper respiratory tract infection 4.2%
diarrhoea 3.5%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
nausea 25.8%
diarrhea 14.9%
vomiting 11.9%
NCT01191268 · Phase 3 · registry result, not featured evidence
0.75 mg
nausea 17.7%
diarrhea 11.6%
vomiting 10.6%
NCT01191268 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.4%
headache 5.9%
diarrhoea 4.3%
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 5.3%
headache 4.8%
viral infection 3.7%
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 6.8%
headache 3.4%
influenza 3.4%
NCT01194258 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 11.9%
diarrhoea 8.5%
nasopharyngitis 5.1%
NCT01194258 · Phase 2 · registry result, not featured evidence
abdominal pain 4.5%
diarrhoea 4.5%
injection site pain 4.5%
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
headache 13.6%
nausea 9.1%
abdominal pain 4.5%
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
catheter site related reaction 12.5%
upper respiratory tract infection 12.5%
urinary tract infection 12.5%
NCT02197520 · Phase 1 · registry result, not featured evidence
covid-19 8.3%
bronchitis 5.6%
dermatitis allergic 5.6%
NCT05893797 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 48 weeks versus 24 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 3 versus Phase 4.
  6. fAssessment timepoints differ: 24 weeks versus 60 weeks.
  7. gPopulation comparability has not been reviewed for these studies.
  8. hPopulation comparability has not been reviewed for 18 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin glulisine

HbA1c -2.3% (n=138) vs -1.97% (n=134) Novolog Mix 70/30 @ 60wk
absolute change · percentage points
Absolute change in HbA1c from baseline
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Severe or BG Confirmed Hypoglycemia 23% (n=183) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
responder rate · % of participants
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
25% (n=180) vs 14.1% (n=185) Novolog Mix 70/30 @ 60wk
HbA1c < 7.0%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
Daily Plasma Glucose Change mg/dL -0.83 vs -0.11 Insulin Glargine+Metformin+Glimepiride mmol/L @ 24wk
absolute change · mmol/L
NCT00360698 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -15.01 mg/dL as posted
Symptomatic Hypoglycemia 8.19% (n=49) vs 7.68% (n=57) Insulin Glargine+Metformin+Glimepiride
event rate · % of participants
NCT00360698 · Phase 4 · registry result, not featured evidence · combination

Insulin Lispro

HbA1c Less Than 7% 30.3% (n=158) vs 24.2% (n=163) Glargine @ 16wk
responder rate · % of participants
Week 16 HbA1c <=7.0% (n=157, n=155)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 18.7% (n=158) vs 14.6% (n=163) Glargine @ 16wk
responder rate · % of participants
Week 16 HbA1c <=6.5% (n=157, n=155)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 37.6% (n=158) vs 32.1% (n=163) Glargine @ 32wk
responder rate · % of participants
Week 32 HbA1c <=7.0% (n=137, n=141)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 20.6% (n=158) vs 19% (n=163) Glargine @ 32wk
responder rate · % of participants
Week 32 HbA1c <=6.5% (n=137, n=141)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 48.2% (n=158) vs 36.2% (n=163) Glargine @ 48wk
responder rate · % of participants
Week 48 HbA1c <=7.0% (n=130, n=137)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 24.8% (n=158) vs 18.5% (n=163) Glargine @ 48wk
responder rate · % of participants
Week 48 HbA1c <=6.5% (n=130, n=137)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 21.4% (n=131) vs 18.5% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
responder rate · % of participants
HbA1c <7%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
A1C Less Than 6 5 11.5% (n=131) vs 6.7% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
responder rate · % of participants
HbA1c ≤6.5%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
PP 2 h Glucose mg/dL 163.4 vs 178.2 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
PPG 2 h Excursion mg/dL 17 vs 36.1 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
Fasting Plasma Glucose mg/dL 161.1 vs 153.9 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
Fasting
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Nocturnal Hypoglycemia 38.6% (n=361) vs 35.9% (n=362) Insulin Glargine @ 26wk
responder rate · % of participants
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
show 1 more result
23.7% (n=684) vs 12.2% (n=672) Insulin Glargine + Insulin Lispro @ 26wk
NCT01468987 · Phase 3 · registry result, not featured evidence · combination

+ 45 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glulisine's landscape · Insulin Lispro's landscape